Literature DB >> 14583499

Proteomic profiling of urinary proteins in renal cancer by surface enhanced laser desorption ionization and neural-network analysis: identification of key issues affecting potential clinical utility.

Mark A Rogers1, Paul Clarke, Jason Noble, Nicholas P Munro, Alan Paul, Peter J Selby, Rosamonde E Banks.   

Abstract

Recent advances in proteomic profiling technologies, such as surface enhanced laser desorption ionization mass spectrometry, have allowed preliminary profiling and identification of tumor markers in biological fluids in several cancer types and establishment of clinically useful diagnostic computational models. There are currently no routinely used circulating tumor markers for renal cancer, which is often detected incidentally and is frequently advanced at the time of presentation with over half of patients having local or distant tumor spread. We have investigated the clinical utility of surface enhanced laser desorption ionization profiling of urine samples in conjunction with neural-network analysis to either detect renal cancer or to identify proteins of potential use as markers, using samples from a total of 218 individuals, and examined critical technical factors affecting the potential utility of this approach. Samples from patients before undergoing nephrectomy for clear cell renal cell carcinoma (RCC; n = 48), normal volunteers (n = 38), and outpatients attending with benign diseases of the urogenital tract (n = 20) were used to successfully train neural-network models based on either presence/absence of peaks or peak intensity values, resulting in sensitivity and specificity values of 98.3-100%. Using an initial "blind" group of samples from 12 patients with RCC, 11 healthy controls, and 9 patients with benign diseases to test the models, sensitivities and specificities of 81.8-83.3% were achieved. The robustness of the approach was subsequently evaluated with a group of 80 samples analyzed "blind" 10 months later, (36 patients with RCC, 31 healthy volunteers, and 13 patients with benign urological conditions). However, sensitivities and specificities declined markedly, ranging from 41.0% to 76.6%. Possible contributing factors including sample stability, changing laser performance, and chip variability were examined, which may be important for the long-term robustness of such approaches, and this study highlights the need for rigorous evaluation of such factors in future studies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14583499

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  42 in total

1.  SELDI-TOF derived serum biomarkers failed to differentiate between patients with beryllium sensitisation and patients with chronic beryllium disease.

Authors:  B C Tooker; R P Bowler; J M Orcutt; L A Maier; H M Christensen; L S Newman
Journal:  Occup Environ Med       Date:  2011-01-27       Impact factor: 4.402

Review 2.  Classification algorithms for phenotype prediction in genomics and proteomics.

Authors:  Habtom W Ressom; Rency S Varghese; Zhen Zhang; Jianhua Xuan; Robert Clarke
Journal:  Front Biosci       Date:  2008-01-01

Review 3.  [Identification of biomarkers and therapeutic targets for renal cell cancer using ProteinChip technology].

Authors:  K Junker; F von Eggeling; J Müller; T Steiner; J Schubert
Journal:  Urologe A       Date:  2006-03       Impact factor: 0.639

4.  Preliminary study on proteomics of gastric carcinoma and its clinical significance.

Authors:  Hong-Gang Qian; Jing Shen; Hong Ma; Hua-Chong Ma; Ya-Hui Su; Chun-Yi Hao; Bao-Cai Xing; Xin-Fu Huang; Cheng-Chao Shou
Journal:  World J Gastroenterol       Date:  2005-10-28       Impact factor: 5.742

5.  High-resolution proteome/peptidome analysis of peptides and low-molecular-weight proteins in urine.

Authors:  Harald Mischak; Bruce A Julian; Jan Novak
Journal:  Proteomics Clin Appl       Date:  2007-07-10       Impact factor: 3.494

6.  Biomarkers of lupus nephritis determined by serial urine proteomics.

Authors:  Xiaolan Zhang; Ming Jin; Haifeng Wu; Tibor Nadasdy; Gyongyi Nadasdy; Nathan Harris; Kari Green-Church; Haikady Nagaraja; Daniel J Birmingham; Chack-Yung Yu; Lee A Hebert; Brad H Rovin
Journal:  Kidney Int       Date:  2008-07-02       Impact factor: 10.612

Review 7.  Application of proteomic analysis to the study of renal diseases.

Authors:  Matthew P Welberry Smith; Rosamonde E Banks; Steven L Wood; Andrew J P Lewington; Peter J Selby
Journal:  Nat Rev Nephrol       Date:  2009-10-27       Impact factor: 28.314

8.  Assessment of Protein Stability in Cerebrospinal Fluid Using Surface-Enhanced Laser Desorption/Ionization Time-of-Flight Mass Spectrometry Protein Profiling.

Authors:  Srikanth Ranganathan; Anna Polshyna; Georgina Nicholl; James Lyons-Weiler; Robert Bowser
Journal:  Clin Proteomics       Date:  2006-03-01       Impact factor: 3.988

9.  Association of serum amyloid A protein and peptide fragments with prognosis in renal cancer.

Authors:  S L Wood; M Rogers; D A Cairns; A Paul; D Thompson; N S Vasudev; P J Selby; R E Banks
Journal:  Br J Cancer       Date:  2010-06-08       Impact factor: 7.640

10.  Identification of macrophage migration inhibitory factor and human neutrophil peptides 1-3 as potential biomarkers for gastric cancer.

Authors:  Y Mohri; T Mohri; W Wei; Y-J Qi; A Martin; C Miki; M Kusunoki; D G Ward; P J Johnson
Journal:  Br J Cancer       Date:  2009-06-23       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.